Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy